Photo by Lia Lora | The Triangle
In May 2026, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping federal plan targeting the “overuse” of psychiatric medication, specifically selective serotonin reuptake inhibitors like Prozac, Zoloft, Lexapro, and Paxil. Announced at a Make America Healthy Again Institute mental health summit, the plan has drawn both cautious support and sharp pushback, with experts warning that it oversimplifies a crisis that has biological, developmental, social, and economic roots.
The policy itself is outlined in a joint federal directive signed by the Substance Abuse and Mental Health Services Administration, the Centers for Medicare & Medicaid Services, the Health Resources and Services Administration, and the Administration for Children and Families. Notably, the tone of the letter is more measured than Kennedy’s other public remarks, stating that psychiatric medications can be “important and, at times, essential” and warning against abrupt discontinuation. The letter emphasizes that medications can “reduce symptoms, improve functioning, prevent relapse, and support recovery,” and defines deprescribing as “a deliberate, individualized clinical process” rather than a blanket reduction in medication use.
The initiative centers on three primary strategies: expanding provider training, developing new clinical guidance, and modifying insurance reimbursement policies through CMS. Federal agencies will also publish updated prescribing trend data and promote access to evidence-based alternatives such as psychotherapy and family support services. Particular attention is given to vulnerable populations, including children, adolescents, older adults, pregnant, postpartum individuals, and patients taking multiple psychiatric medications. Foster youth are specifically identified as being at heightened risk for overprescribing.
Some experts agree that the letter highlights legitimate concerns. “HHS’s Dear Colleague Letter is not wrong in highlighting these shortcomings or the importance of psychotherapy and physical activity in treating depression,” says Dr. Benjamin Cocchiaro, Assistant Professor of Community Health and Prevention at the Dornsife School of Public Health, and former member of the Philadelphia Mayor’s Task Force to Combat the Opioid Epidemic. Cocchiaro points out that both interventions have been found noninferior to SSRIs in large meta-analyses, but that the more important question has to do with the intentions of the HHS.
“Talking patients through an episode of depression or anxiety and helping them make an informed choice regarding their treatment is an important and challenging part of my work in primary care,” Cocchiaro told The Triangle. “Less access and constricted choices make that job a lot harder, so it’s important that we ask ourselves whether HHS is acting in good faith to reduce the burden of disease and facilitate the delivery of high-quality primary care by leveling their critiques, or if the recent Dear Colleague Letter is a prelude to policy that will limit access and choice for our patients.”
Kennedy’s broader views on psychiatric medications have long fueled controversy, with him arguing that antidepressants are overprescribed and have caused what he sees as a “dependency crisis driven by overmedicalization.” Among Kennedy’s concerns is that patients often begin treatment without fully understanding potential risks, how long treatment may last, or how medications should eventually be discontinued, framing this as a failure of informed consent. At the same time, Kennedy has made more unsubstantiated suggestions, claiming that antidepressants may contribute to violence and mass shootings, pose fetal health risks, and has compared antidepressant withdrawal to heroin withdrawal. This rhetoric contrasts sharply with the more cautious language used in the federal directive itself.
Central to the debate are the concepts of overprescribing and deprescribing. Overprescribing generally refers to situations in which medications are prescribed to patients who may not need them or are continued beyond the period in which they provide meaningful benefit. Deprescribing, on the other hand, refers to the careful reduction or discontinuation of medications when benefits no longer outweigh risks or when patients, after informed discussion, prefer to taper treatment.
Dr. Stephanie Matt, Research Assistant Professor in the Department of Pharmacology & Physiology at Drexel University College of Medicine cautions against overly simplistic interpretations of prescribing data. “Antidepressants are neither miracle drugs nor useless medications,” Matt said. “What may appear to be overuse in some cases can reflect the reality that patients respond differently to treatment and that clinicians often need to adjust treatment over time based on effectiveness and tolerability.”
Dr. Wei Du, Professor and Academic Chair of Psychiatry at Drexel University College of Medicine notes that deprescribing is not a new concept and traces its roots to the emergence of “responsible prescribing” practices developed in response to the opioid epidemic. “What we need to promote is responsible prescribing,” Du said. “Take thorough history, review medical records carefully, start medications after informed consent, promote shared decision making with our patients, monitor treatment response and treatment emergent side effects, and adjust dose including planned treatment termination.”
The federal letter similarly points to psychotherapy, social connection, behavioral interventions, sleep-focused treatments, exercise, and dietary modifications as evidence-based alternatives or complements to medication. It also cites a 2026 American Society of Clinical Psychopharmacology consensus statement as the foundation for its deprescribing recommendations.
Yet many experts argue that the debate over psychiatric medications overlooks deeper causes of psychological distress. Dr. Sandra Bloom, Associate Professor of Health Management and Policy at the Dornsife School of Public Health, believes the conversation often becomes trapped in a false choice between biological and social explanations.
“We keep oscillating between biological explanations and social explanations, when human suffering emerges from both,” Bloom said. “Trauma, development, relationships, culture, biology, and meaning all matter. Whenever we reduce people to only one level of explanation, we lose something essential.”
Bloom points to the Adverse Childhood Experiences Study, a landmark collaboration between the Centers for Disease Control and Prevention and Kaiser Permanente that examined more than 17,000 adults. The study found a strong relationship between childhood adversity and later physical, emotional, and behavioral health problems. As researchers concluded, the greater the number of adverse experiences a person endured during childhood, the greater the likelihood of serious difficulties later in life.
“I practiced through several eras of psychiatry,” Bloom said. “I witnessed the excitement surrounding the development of psychopharmacological agents in the 1970s, saw the benefits for many patients, but also watched what happened as biological explanations increasingly displaced social and developmental ones.”
At the same time, Bloom notes that even the ACE framework has limitations because it focuses largely on household experiences and does not fully account for larger social systems, economic conditions, and institutional factors that contribute to adversity. The implication, Bloom argues, is that mental health cannot be improved simply by changing prescribing patterns. Broader conditions that generate distress must also be addressed.
Reactions from the psychiatric community have been mixed. With more than 40,000 physician members, the American Psychiatric Association has welcomed increased investment in research, provider training, and access to evidence-based care. However, the organization argues that framing the mental health crisis primarily as a problem of overmedicalization ignores the reality that countless patients struggle to access timely and comprehensive treatment.
In a statement addressing the HHS letter, the American Psychiatric Association stated that “the solution is not to stigmatize psychiatric medication or impose broad assumptions on clinical care, but to ensure that patients have access to the full range of evidence-based treatments and that decisions are guided by the best available science and each patient’s needs.”
Organizations such as the Child Mind Institute and the American Foundation for Suicide Prevention warn that focusing exclusively on SSRI side effects obscures the fact that these medications have helped millions of patients, and argue that there is extensive evidence showing that antidepressants can reduce suicidal thoughts and behaviors and lower overall suicide risk. Dr. Matt echoes these concerns, arguing that while prescribing practices should continue to improve and patient preferences should play a larger role in decision-making, reducing access to medication could unintentionally harm those who need care most.
Critics also claim that the plan risks overlooking deeper structural problems within the mental health system. While concerns about overprescribing are not new, many experts point out that millions of Americans still struggle to access timely and comprehensive mental health care. Persistent barriers include shortages of mental health professionals, limited access to psychotherapy, inadequate psychiatric resources, and gaps in the integration of mental health services into primary care. Depression remains one of the most significant public health challenges worldwide, and many patients do not respond fully to existing treatments. As a result, some clinicians worry that focusing primarily on medication use may distract from broader efforts to expand access to the full range of evidence-based mental health services.
For patients currently taking psychiatric medications, experts emphasize that no one should stop treatment without consulting a healthcare professional. Abrupt discontinuation can cause serious withdrawal symptoms and increase the risk of relapse. The federal directive itself stresses that tapering should occur in a “safe, thoughtful, and collaborative manner” and should not undermine patient trust, safety, or continuity of care. Organizations such as the Child Mind Institute have long recommended medically supervised tapering protocols for patients considering medication changes.
Bloom offers perhaps the clearest summary of the balance many clinicians are trying to strike: “Medication should never substitute for understanding the developmental, relational, traumatic, social, and economic conditions that contribute to suffering. But neither should concern about overmedication become a reason to deny people treatments that may help them function, survive, and recover.”
Ultimately, the controversy surrounding Kennedy’s initiative may be as much about framing as policy. The official federal directive is considerably more nuanced than many of Kennedy’s public statements, and several of its goals, including improved training, stronger informed consent practices, and expanded access to psychotherapy, align with reforms many psychiatrists already support. Yet the political context and rhetoric surrounding the proposal have complicated its reception.
As Bloom suggests, the deeper question extends beyond antidepressants themselves: what conditions created this debate, what has society neglected in its understanding of mental health, and what would a healthier system look like? The danger, many experts warn, is that in a discussion increasingly shaped by ideology on all sides, the patients most in need of individualized, evidence-based care may ultimately be the ones who suffer the consequences.